Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,585 recruiting studies in this area right now.
By phase
- Not applicable9,775
- Phase 24,443
- Phase 12,736
- Phase 1/Phase 21,691
- Phase 31,397
- Phase 2/Phase 3281
- Phase 4262
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer651
- Colorectal Cancer495
- Lung Cancer424
- Ovarian Cancer340
- Multiple Myeloma333
- Gastric Cancer297
- Pancreatic Cancer293
- Acute Myeloid Leukemia292
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer224
- Endometrial Cancer206
- Advanced Solid Tumors192
- Bladder Cancer191
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic242
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas637
- Arizona512
- Florida448
- Alabama418
- New York408
- Massachusetts342
- Maryland329
- New Jersey267
- Pennsylvania247
Recruiting studies20,585 total
- NCT07052877Recruiting
Studying PSMA imaging in glioblastoma with bevacizumab
This trial tests whether adding a special imaging scan (PSMA PET) before and after the drug bevacizumab can help see how the drug affects glioblastoma tumors. It aims to understand tumor changes better, which may help guide future treatments.
Saint Leonards, New South WalesAges 18 years+ - NCT06416410RecruitingPhase 3
Combination targeted therapy for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hefei, AnhuiAges 18 years+ - NCT06762431RecruitingPhase 1/Phase 2
CAR T-cell therapy plus lenalidomide for CLL
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Vitebsk, Select A StateAges 18 years+ - NCT07136701Recruiting
Pancreatic neuroendocrine tumor risk factors and prognosis
This study looks at how pancreatic neuroendocrine tumors behave differently in younger versus older people. It aims to find better ways to predict outcomes and guide treatment.
Jinan, ShandongAges 18–85 - NCT07266428RecruitingPhase 1/Phase 2
Study of a new drug (OTP-01) for advanced solid tumors
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT05612347Recruiting
Compare stool test vs colonoscopy for older adults with polyps
This study compares two ways to check for colon polyps in older adults: using a stool test versus having a colonoscopy. It may help find a simpler option if you only had a small number of lower-risk polyps before.
Birmingham, AlabamaAges 65–82 - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT05733715RecruitingEarly Phase 1
Testing pembrolizumab plus lenvatinib before kidney cancer surgery
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05534386Recruiting
Self-management support for Chinese cancer survivors
This trial tests a self-management program to help Chinese cancer survivors after treatment. It may help you build practical skills for recovery and day-to-day health after cancer treatment ends.
Hong KongAges 18 years+ - NCT05679518Recruiting
Therapy to reduce fear of cancer progression
This study tests two types of talking therapy to help people who have recently been diagnosed with advanced cancer and feel strong fear about cancer getting worse. You may be able to join if you can speak Cantonese or Mandarin and can attend a set number of therapy sessions.
Hong KongAges 18 years+ - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07678229RecruitingPhase 3
Immunotherapy vs Chemotherapy for Advanced NK/T-cell Lymphoma
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Boston, MassachusettsAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT05276726RecruitingPhase 1/Phase 2
Test drug JAB-21822 for KRAS G12C NSCLC with STK11
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07147231RecruitingPhase 1/Phase 2
Pidnarulex plus cemiplimab for MSS colorectal cancer
This trial tests two drugs together: pidnarulex (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced colorectal cancer that is microsatellite stable (MSS) and has not responded to current treatments, especially if their tumor has a MYC or FBXW7 change.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07696715Recruiting
Timing of immunotherapy for melanoma
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
AmsterdamAges 18 years+ - NCT04167969RecruitingTeam says not enrollingPhase 1
Nanoparticles to help guide prostate cancer surgery
This Phase 1 study tests nanoparticles (tiny particles) that are meant to help surgeons better find and remove prostate cancer tissue during surgery. You may be offered standard prostate surgery plus imaging with a study tracer to guide the operation.
New York, New YorkAges 18 years+ - NCT05272709RecruitingPhase 1/Phase 2
New pill TT-702 for advanced solid tumors
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
LondonAges 16 years+ - NCT06161519RecruitingPhase 1/Phase 2
PLX038 for brain tumors with MYC or MYCN changes
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Bethesda, MarylandAges 18–120 - NCT07751159RecruitingPhase 2
Comparing radiation therapy methods for prostate cancer
This study compares two types of radiation therapy for prostate cancer that hasn't spread. It aims to find which approach is more effective and has fewer side effects.
Basking Ridge, New JerseyAges Any age
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,585 recruiting oncology studies from the U.S. registry right now, out of 31,101 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.